| Study Period |
Patient Population |
N |
Any mutation (%) |
NNRTI (%) |
NRTI (%) |
PI (%) |
Reference |
| 2011 |
Treatment naïve women |
351 |
7.4 |
5.7 |
2.0 |
0.6 |
Parikh et al. [13] |
| 2010 |
HIV surveillance |
72 |
0.0 |
0.0 |
0.0 |
0.0 |
Manasa et al. [17] |
| 2009 |
ANC Survey |
47 |
<5.0 |
<5.0 (2.1) |
<5.0 |
<5.0 |
Parboosing et al. [14] |
| 2009 |
ANC Survey |
47 |
5-15 |
5-15 |
<5.0 |
<5.0 |
Hunt et al. [15] |
| 2008* |
ANC Survey |
37 |
13.5 |
8.1 |
5.4 |
2.7 |
Hunt et al. [15] |
| 2007 |
ANC Survey |
34 |
<5.0 |
<5.0 |
<5.0 |
<5.0 |
Hunt et al. [15] |
| 2005* |
ANC Survey |
40 |
2.5 |
2.5 |
ND |
ND |
Hunt et al. [15] |
| 2003 |
Treatment naïve adults |
56 |
<5.0 |
<5.0 (2.1) |
<5.0 |
<5.0 |
Gordon et al. [16] |
* The threshold level could not be determined because of insufficient numbers of samples genotyped.
N - number of patients genotyped; NNRTI - Non-nucleoside reverse transcriptase inhibitor; ND - not determined; NRTI - nucleoside reverse transcriptase inhibitor; PI -
protease inhibitor; |
